Identification of 1,5-Naphthyridine Derivatives As a Novel Series of Potent and Selective TGF-Â Type I Receptor Inhibitors
4494 J. Med. Chem. 2004, 47, 4494-4506 Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-â Type I Receptor Inhibitors Franc¸oise Gellibert,*,† James Woolven,‡ Marie-He´le`ne Fouchet,† Neil Mathews,§,| Helen Goodland,| Victoria Lovegrove,| Alain Laroze,† Van-Loc Nguyen,† Ste´phane Sautet,† Ruolan Wang,⊥ Cheryl Janson,#,× Ward Smith,∇,× Gae¨l Krysa,X Vale´rie Boullay,X Anne-Charlotte de Gouville,X Ste´phane Huet,X and David Hartley| Departments of Medicinal Chemistry and Biology, GlaxoSmithKline, 25-27 Avenue du Que´bec, 91951 Les Ulis, France, Discovery Research, Computational and Structural Science, and Department of Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom, Discovery Research, Assay Development and Compound Profiling, GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709, and Discovery Research, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 Received January 30, 2004 Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-â type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 ) 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited selectivity over p38 mitogen-activated protein kinase. The X-ray crystal structure of 19 in complex with human ALK5 is described, confirming the binding mode proposed from docking studies. Introduction Chart 1 Transforming growth factor (TGF-â) is a pluripotent cytokine involved in a variety of biological processes such as development, cell growth, differentiation, cell adhesion, migration, extracellular matrix (ECM) deposi- tion, and immune response regulation.1 This cytokine regulates not only the ECM deposition in response to tissue injury, thus contributing to the healing process, the GS domain.
[Show full text]